Trial Profile
A phase 1b study of ANS-6637 and buprenorphine
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2019
Price :
$35
*
At a glance
- Drugs ANS 6637 (Primary) ; Buprenorphine
- Indications Alcoholism; Opioid-related disorders; Smoking withdrawal; Substance-related disorders
- Focus Adverse reactions
- 04 Apr 2019 New trial record
- 28 Mar 2019 According to an Amygdala Neurosciences media release, the company today announced the start of dosing in this NIH/NIAID study.